Kodiak Sciences Q2 net loss misses estimates

Kodiak Sciences

13/08/2025 21:11

Overview

Kodiak Q2 net loss of $54.3 mln missed analyst expectations

Operating income for Q2 beat estimates, driven by clinical study activities

Cash position at $104.2 mln, supporting operations into 2026

Result Drivers

CLINICAL TRIALS - Increased R&D expenses driven by active Phase 3 studies for tarcocimab, KSI-501, and KSI-101

CASH POSITION - Cash reserves of $104.2 mln expected to support operations into 2026

MANUFACTURING - Completion of commercial-scale batches at URSUS facility for upcoming BLA submissions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$1.03
Q2 Net Income
Miss
-$54.31 mln
-$53.70 mln (3 Analysts)
Q2 Operating Income
Beat
-$55.51 mln
-$57.60 mln (4 Analysts)
Q2 Basic EPS
-$1.03
Q2 Operating Expenses
$55.51 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Kodiak Sciences Inc is $3.50, about 143.4% below its August 12 closing price of $8.52

Press Release: ID:nPnbpvHTFa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)